Stratec SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STSEY research report →
Price Chart
About the company
Stratec SE, an international company with various subsidiaries, focuses on developing and manufacturing automated instruments and sophisticated solutions for the in-vitro diagnostics and life sciences industries. Its commercial reach extends across Germany, the broader European Union, and other global regions. The company's operations are divided into three primary segments: Instrumentation, Diatron, and Smart Consumables.
- CEO
- Marcus Wolfinger
- IPO
- 2020
- Employees
- 1,403
- HQ
- Birkenfeld, RP, DE
Get TickerSpark's AI analysis on STSEY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.67B
- P/E
- -540.00
- PEG
- 8.30
- P/S
- 1.07
- P/B
- 1.10
- EV/EBITDA
- 11.43
- Div Yield
- 2.78%
- Gross Margin
- 23.57%
- Op Margin
- 2.65%
- Net Margin
- -0.16%
- ROE
- -0.17%
- ROIC
- -0.12%
Latest fiscal year · YoY change
- Revenue
- $250.86M-2.6%
- Gross Profit
- $64.22M-15.9%
- Op Income
- $10.69M
- Net Income
- $-242,000-101.5%
- EPS
- $-0.00-101.5%
- OCF Growth
- -100.9%
- FCF Growth
- -154.6%
- 52W High
- $6.70
- 52W Low
- $5.00
- 50D MA
- $5.51
- 200D MA
- $5.35
- Beta
- 0.81
- RSI (14)
- 99
- Avg Volume
- 80
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
STRATEC said H1 2026 was weak on revenue but better on profitability and cash flow, with strong systems growth and a back-end-loaded full-year outlook still intact.· August 14, 2026
- H1 revenue was EUR 112.5 million, down 5.1% nominally and 3.3% in constant currency.
- Adjusted EBIT was EUR 7.7 million, with margin at 6.9% versus 7.2% last year; EBITDA margin was 13.9%.
- Free cash flow improved sharply to EUR 23.5 million from negative EUR 14.7 million last year, helped by lower receivables and lower tax payments.
- Systems revenue rose 15.4% to EUR 39.7 million, while service parts and consumables fell 11.9% and services fell 7.8% on a constant-currency basis.
- Management confirmed 2026 guidance: medium to high single-digit sales growth, full-year adjusted EBIT margin around last year’s 10%, and CapEx at 6.5% to 8.5% of sales.
For H1 2026, STRATEC reported revenue of EUR 112.5 million, down 5.1% year over year, or 3.3% on a constant-currency basis. Adjusted EBIT was EUR 7.7 million versus EUR 8.5 million a year ago, with adjusted EBIT margin at 6.9% versus 7.2%; EBITDA margin improved slightly to 13.9%. Adjusted net income was EUR 4.1 million, or EUR 0.34 per share, and reported IFRS net income was EUR 2.4 million, or EUR 0.20 per share. Free cash flow was EUR 23.5 million versus negative EUR 14.7 million last year, operating cash flow was EUR 29.7 million versus negative EUR 5.8 million, net debt fell to EUR 96.7 million, and net debt/LTM EBITDA improved to 2.9x from 3.3x. By segment, systems revenue increased 15.4% to EUR 39.7 million, service parts and consumables were EUR 46.1 million and down 11.9% constant currency, and services declined 7.8% constant currency. For full-year 2026, management reaffirmed medium to high single-digit revenue growth on a constant-currency basis, adjusted EBIT margin expected to be approximately at the prior-year level of 10%, and CapEx in a range of 6.5% to 8.5% of sales. Management said Q4 is expected to remain heavily back-end loaded, historically contributing about 30% to 33% of annual revenue and possibly toward the top end of that range again.
Marcus Wolfinger emphasized that Q2 performance improved meaningfully and helped narrow the H1 gap, but he repeatedly framed the year as very back-end loaded. His tone was constructive but cautious: systems demand is strong, life cycle management projects remain active, and 2026 guidance was reaffirmed, yet consumables and maintenance parts were described as exceptionally weak and the broader environment as volatile. He also highlighted structural efforts around cost discipline, electronics supply risk, and pipeline building for growth beyond 2032.
Tanja Bucherl focused on the financial bridge from weak top line to better earnings and cash. She cited H1 revenue of EUR 112.5 million, adjusted EBIT of EUR 7.7 million, reported EBIT of about EUR 5.5 million, adjusted net income of EUR 4.1 million, and free cash flow of EUR 23.5 million; she also noted operating cash flow of EUR 29.7 million and lower net debt at EUR 96.7 million. She said the margin was pressured by negative scaling and a less favorable mix, especially the lower share of higher-margin service parts and consumables, but that cost discipline, structural actions, exchange rates, and stronger Q2 leverage helped. CapEx remained below the guided corridor in H1, but she said the company is still sticking to the 6.5% to 8.5% target and watching the volatile environment closely.
Analysts pressed on supply-chain risk, the persistent weakness in consumables, the effectiveness of new forecasting systems, H2 phasing, and CapEx timing. Management said it is not immune to supply issues or electronics lead-time inflation, but it is better prepared than in prior crises and is trying to pass through exceptional cost pressure where contractual terms allow. On consumables, Marcus Wolfinger said weakness is mainly tied to customer inventory optimization and M&A-related service-stock reductions rather than a broad utilization problem, while also acknowledging some uncertainty about the timing of recovery. On H2, he reiterated that Q4 should again dominate the year and that Q3 should be in the same absolute ballpark as Q2, while Tanja Bucherl said CapEx is still guided at 6.5% to 8.5% with no pre-investment phase expected.
The bull case from the call is that systems demand is growing strongly, especially in immunoassay, molecular diagnostics, and immunohematology, and management sees this as evidence of underlying growth momentum in the core business. Cash generation also turned sharply positive, net debt fell, and management reaffirmed full-year guidance while pointing to a substantial Q4 contribution and a pipeline of future product launches.
The main bear case is that H1 sales declined, consumables and maintenance parts were exceptionally weak, and management repeatedly said recovery depends on customer inventory normalization and volatile order timing. The company also flagged ongoing electronics supply and pricing pressure, elevated inventories, and the risk that the year remains highly back-end loaded if Q4 execution slips. Management also said Natech integration is behind plan, which suggests some acquisition-related execution risk remains.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 10.9%
- Shares Outstanding
- 303.90M
- Float Shares
- 33.15M
Our STSEY coverage
Recent articles, reports, and earnings notes.
No research on STSEY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STSEY report →Stratec SE ADR (STSEY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 14
Stratec SE ADR (STSEY) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 12
Stratec SE ADR (STSEY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Apr 29
Stratec SE ADR (STSEY) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.